Skip to main content
MIRM
NASDAQ Life Sciences

Brelovitug Hits Phase 3 Primary Endpoint in HDV, Paving Path to BLA

Tom Rudovsky · Reported by BusinessWire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$91.99
Mkt Cap
$5.824B
52W Low
$63.232
52W High
$130
52W Position info
45% above low
Off High info
29% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

MIRM sits 45% above its 52-week low of $63.232.

Summary

Mirum's brelovitug met the primary endpoint in the Phase 3 AZURE-1 study for chronic hepatitis delta virus (HDV), with 56% of patients on the 300mg weekly dose and 45% on the 900mg monthly dose achieving combined virologic response and ALT normalization at Week 24, versus 0% in the delayed treatment arm (p<0.0001). The 48-week Phase 2b data showed deepening viral suppression, with 80% of patients on the 300mg dose achieving HDV RNA below the lower limit of quantification, up from 45% at Week 24, and 55% of patients in both dose arms achieved the combined endpoint. Safety was clean with no Grade 3+ adverse events in the treatment arms. This is the first of two pivotal studies needed for U.S. registration; topline results from the second study, AZURE-4, are expected in Q4 2026, with a BLA submission planned for H1 2027 and potential U.S. launch in Q4 2027. The company will host a conference call at 8:30 a.m. ET today to discuss the results. This follows the FDA approval of Atebrioz for FOP just three days ago, adding to a strong clinical momentum for Mirum's rare disease pipeline. Mirum estimates brelovitug annual revenue potential over $1 billion and Atebrioz over $200 million.

Updated with an SEC 8-K filing · What changed

Updates

  1. · SEC 8-K — The 8-K adds Phase 2b 48-week data: 55% of patients in both dose arms achieved the combined endpoint, and 80% on 300mg had HDV RNA below LLOQ. Mirum estimates brelovitug annual revenue potential over $1 billion and Atebrioz over $200 million.

At the time of this announcement, MIRM was trading at $91.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.8B. The 52-week trading range was $63.23 to $130.00. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: BusinessWire.


Price Chart

Share this article

Copied!

MIRM - Latest Insights

MIRM
Nov 03, 2026, 4:06 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $87.03
Real-time Price: $88.22 info
Change: +$1.19 (+1%) info
Market Cap: $5.651B info
MIRM
Nov 03, 2026, 4:03 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $87.03
Real-time Price: $88.22 info
Change: +$1.19 (+1%) info
Market Cap: $5.651B info
MIRM
Nov 03, 2026, 4:01 PM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $87.03
Real-time Price: $88.22 info
Change: +$1.19 (+1%) info
Market Cap: $5.651B info
MIRM
Oct 26, 2026, 8:00 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $80.15
Real-time Price: $88.22 info
Change: +$8.07 (+10%) info
Market Cap: $5.651B info
MIRM
Oct 13, 2026, 8:09 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $86.20
Real-time Price: $88.22 info
Change: +$2.02 (+2%) info
Market Cap: $5.651B info